Johnson & Johnson has announced a sweeping settlement expected to resolve nearly all pending lawsuits alleging that its talc-based products, including its iconic baby powder, caused ovarian cancer. The agreement is estimated to cost the healthcare giant around **$5.5 billion**, though the final amount could rise depending on how many eligible claimants join the settlement.
The proposed resolution covers approximately **76,000 existing claims**, including cases consolidated in federal court in New Jersey as well as related proceedings in various state courts. It represents one of the most significant developments in a legal battle that has shadowed the company for more than a decade. Johnson & Johnson had previously settled the majority of lawsuits claiming its talc products caused mesothelioma through alleged asbestos contamination.
The agreement is not yet final. It requires approval from **95% of ovarian cancer claimants** involved in the state and federal litigation before it can take effect.
Despite agreeing to settle, Johnson & Johnson continues to reject the allegations. The company maintains that its talc products were safe, did not contain asbestos, and did not cause cancer. Company executives said the decision to settle was driven by a desire to bring long-running litigation to a close rather than by any admission of wrongdoing.
According to the company, approximately **$3 billion** is expected to be paid in 2027, with additional payments scheduled for 2028. However, the total payout remains open-ended because compensation will depend on the number of eligible claimants who participate.
Lawyers representing plaintiffs described the settlement as a favorable outcome after years of litigation. One of the attorneys involved in negotiating the agreement indicated that Johnson & Johnson’s eventual financial commitment could exceed **$7 billion**, noting that while individual claims have predetermined settlement values, there is no overall cap on the company’s total liability under the deal.
## Settlement Follows Favorable Court Developments
The settlement comes after Johnson & Johnson secured a series of courtroom successes. In recent years, the company prevailed in several individual trials, obtained rulings limiting the participation of certain plaintiffs’ attorneys, and successfully challenged expert testimony relied upon by claimants.
A significant development came only days before the settlement announcement, when a federal judge questioned whether individual plaintiffs could sufficiently establish that talc specifically caused their ovarian cancer, a ruling viewed as strengthening the company’s legal position.
Johnson & Johnson has consistently argued that scientific evidence supports the safety of its talc products. The company discontinued sales of talc-based baby powder in the United States in 2020 and replaced it with a cornstarch-based version.
## Bankruptcy Strategy Abandoned
The litigation had remained largely paused for more than three years while Johnson & Johnson pursued a controversial bankruptcy strategy aimed at resolving the lawsuits through a subsidiary. The approach, commonly referred to as the “Texas two-step,” involved placing talc liabilities into a separate entity that then sought bankruptcy protection.
Courts ultimately rejected each of the three bankruptcy filings, allowing the litigation to resume in 2025.
Before those bankruptcy efforts, Johnson & Johnson experienced mixed results in court. While it successfully defended several lawsuits and saw some large verdicts reduced on appeal, it also faced substantial judgments, including a multi-billion-dollar award in favor of women who alleged the company’s baby powder contributed to their ovarian cancer.
Unlike the earlier bankruptcy proposals, the latest settlement applies **only to existing claims** and does not cover future lawsuits. Attorneys involved in the negotiations said excluding future claims made it possible to increase compensation for current claimants while significantly accelerating payouts, with eligible participants expected to receive compensation within approximately **18 months**, rather than over many years.
